GENERAL
Morepen Laboratories Q2 PAT Rises 117% To ₹89 Cr On CDMO Growth
Morepen Laboratories Ltd reported a 117% year-on-year increase in profit after tax (PAT) to ₹89 crore for Q2 FY27, driven by the scale-up of contract development and manufacturing organisation (CDMO) supplies, improving business mix and higher operating leverage. Revenue rose 81% to ₹755 crore in the quarter ended September 30, 2026. EBITDA surged 273% year-on-year […]
CW Bureau
·
Oct 27, 2026
GENERAL
Pharma Sector Revenue Growth Seen At 11-13% This Fiscal: Crisil Ratings
India’s pharmaceutical sector is expected to see revenue growth accelerate to 11-13% this fiscal from 8% last fiscal, supported by stronger exports and firmer domestic demand, according to Crisil Ratings. However, the improvement in revenue is unlikely to translate fully into earnings as higher raw material, energy and freight costs are expected to put pressure […]
CW Bureau
·
Sep 24, 2026
GENERAL
Kwality Pharma Ups FY27 Guidance, Targets ₹1,000 Cr Revenue By FY29
Kwality Pharmaceutical Ltd, which has doubled its turnover to ₹500 crore in three years, has raised its FY27 revenue guidance to over ₹700 crore from ₹650 crore and is targeting more than ₹1,000 crore by FY29. “Over the longer term, we continue to work toward doubling revenue over the next three years, with a goal […]
CW Bureau
·
Aug 10, 2026
GENERAL
Aurobindo Pharma Bets On Specialty Drugs, Biosimilars For Next Expansion
Aurobindo Pharma Ltd is doubling down on high-value specialty medicines, biosimilars and complex formulations while strengthening its manufacturing footprint and supply chain resilience as it charts its next phase of global growth. In his message to shareholders in the company’s Annual Report 2026, Vice Chairman & Managing Director K. Nithyananda Reddy said the company will […]
CW Bureau
·
Aug 4, 2026
